Lepu Biopharma (HKG:2157) completed a filing with the China Securities Regulatory Commission for the conversion of its 54,268,364 unlisted domestic shares and their issuance as H shares on the Hong Kong bourse, according to a Wednesday filing with the exchange.
Shares in the biopharmaceutical company rose 2% during morning trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。